Transmission of Mental Disorders in Adolescent Peer Networks

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.1126?guestAccessKey=77db5a33-85ba-4b33-b47f-d704d07709bd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052224

 

About The Study: The findings of this study suggest that mental disorders might be transmitted within adolescent peer networks. More research is required to elucidate the mechanisms underlying the possible transmission of mental disorders. 

Corresponding Author: To contact the corresponding author, Jussi Alho, Ph.D., email jussi.alho@helsinki.fi.

 

(10.1001/jamapsychiatry.2024.1126)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Firearm Homicide Demographics Before and After the COVID-19 Pandemic

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12946?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this study, death by firearm homicide was concentrated among Black individuals ages 15 to 24 before, during, and subsequent to the COVID-19 pandemic, implying that there are likely to be social and structural conditions that contribute to these racial disparities. 

Corresponding Author: To contact the corresponding author, Alex R. Piquero, Ph.D., email axp1954@miami.edu.

 

(doi:10.1001/jamanetworkopen.2024.12946)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7112?guestAccessKey=0a614c40-2196-4a8c-a050-5957fbbc225a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052224

 

About The Study: Between 2020 and 2023, the number of adolescents and young adults with glucagon-like peptide-1 receptor agonist (GLP-1RA) dispensing increased substantially. In contrast, the number with dispensing of other drugs decreased. Increases in GLP-1RA dispensing were greatest for females, highlighting the importance of educating patients and prescribers on sex-specific safety risks (e.g., concerns during pregnancy). 

 

Quote from corresponding author Joyce M. Lee, M.D., M.P.H.:

“Little is known about the use of GLP-1 RA medications like Wegovy or Ozempic in younger patients. We found that there was a 594% increase in GLP-1 RA medication dispensing between 2020-2023 among adolescents and young adults, highlighting the importance of studying the long-term safety and effectiveness of these medications.

 

“Increases in GLP-1RA dispensing were more pronounced among females than among males. In 2023, 60.0% of adolescents, and 76.4% of young adults dispensed medications were female. This disproportionate dispensing may represent a societal bias towards weight in females and may have implications for the long-term health of girls and women.”

 

Contact information for Joyce M. Lee, M.D., M.P.H.: email joyclee@med.umich.edu.

 

(doi:10.1001/jama.2024.7112)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Socioeconomic Status Transition Throughout Life and Risk of Dementia

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12303?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

  

About The Study: This cohort study of Japanese older adults identified that upward and downward socioeconomic status transitions were associated with risk of dementia and the length of dementia-free periods over the lifespan. The results may be useful to understand the association between social mobility and healthy longevity. 

Corresponding Author: To contact the corresponding author, Hiroyasu Iso, Ph.D., email iso@pbhel.med.osaka-u.ac.jp.

 

(doi:10.1001/jamanetworkopen.2024.12303)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Variations by State in Firearm Suicide Among US Children and Young Adults, 2016-2021

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1128?guestAccessKey=5603ef88-e57e-4355-88a8-18360ee969dc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

No Comments

Filed under:

Bisoprolol in Patients With COPD at High Risk of Exacerbation

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, MAY 19, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8771?guestAccessKey=d4543ce8-c594-44e0-805b-44a020c965ab&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

 

About The Study: Among people with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation, treatment with the β1-selective β-blocker bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both.

Quote from corresponding author Graham Devereux, M.D.:

“People with COPD are at increased risk of cardiovascular conditions that benefit from treatment with beta-blockers. However, there is a well-documented reluctance for physicians to prescribe beta-blockers for people with cardiovascular disease and COPD.

“These findings will help physicians and patients with COPD assess the risks and benefits of using bisoprolol to treat cardiovascular disease.”

 

Contact information for Graham Devereux, M.D.: email graham.devereux@lstmed.ac.uk.

 

(doi:10.1001/jama.2024.8771)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, MAY 19, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8772?guestAccessKey=1b8c1ae9-3edc-4366-be12-3cf2610d148d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

 

About The Study: In critically ill sepsis patients, treatment with intravenous acetaminophen for 5 days was safe but did not improve the primary end point of days alive and free of any organ support (dialysis, assisted ventilation, and vasopressors) to day 28 compared with placebo.  

Corresponding Author: To contact the corresponding author, Lorraine B. Ware, M.D., email Lorraine.ware@vumc.org.

 

(doi:10.1001/jama.2024.8772)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study, editorial and Viewpoint are linked to this news release. This study is being released to coincide with presentation at the Society for Clinical Trials Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.6281?guestAccessKey=d9f07766-1e0a-40a7-b69b-c448469ffc17&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

 

About The Study: Many studies suggest a survival benefit for cancer trial participants. However, these benefits were not detected in studies using designs addressing important sources of bias and confounding. Pooled results of high-quality studies are not consistent with a beneficial effect of trial participation on its own.

 

Quote from corresponding author Jonathan Kimmelman, Ph.D.:

 

“Many physicians, policymakers, patient advocates, and research sponsors believe patients have better outcomes when they participate in trials, even if they are in the comparator arm. Educational materials for patients often encourage patients to consider the better care they might receive in trials. As a member of various review committees, I hear this said all the time. Yet evidence of such a ‘participation effect’ is lacking.

“Many studies have looked at the ‘participation effect’ for patients with cancer. If you pool them altogether, it looks like cancer patients in trials do live longer than patients outside them. But if you restrict analysis to studies that control for various sources of confound (for example, the fact that trials tend to enroll younger and healthier patients) or bias (many studies of participation benefit are probably never published) those survival benefits disappear.

“Our findings provide reassurance that inability to enroll in a cancer trial doesn’t disadvantage a patient, at least in terms of survival. Our findings can help patients (and physicians) focus their consent discussions on the most relevant and evidence-based benefits of trial participation: the prospects of advancing the care of future patients.”

 

Contact information for Jonathan Kimmelman, Ph.D.: email jonathan.kimmelman@mcgill.ca.

 

(doi:10.1001/jama.2024.6281)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Effect of Sleep Restriction on Adolescent Cognition by Adiposity

Posted by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 20, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.1332?guestAccessKey=e6f39acb-146d-41ad-b9ae-5f7000613f06

 

About The Study: Adolescents with overweight or obesity may be more vulnerable to negative cognitive effects following sleep restriction. Improved sleep hygiene and duration in this group may positively impact their cognitive health. 

Corresponding Author: To contact the corresponding author, Aaron D. Fobian, Ph.D., email afobian@uabmc.edu.

 

(doi:10.1001/jamaneurol.2024.1332)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Pamrevlumab for Idiopathic Pulmonary Fibrosis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, MAY 19, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8693?guestAccessKey=822f31af-46d7-4bed-b18f-275b80c4c704&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

 

About The Study: Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in forced vital capacity from baseline to week 48. 

 

Quote from corresponding author, Ganesh Raghu, M.D.:

 

“Current treatment with the two drugs approved by regulatory agencies for the treatment of idiopathic pulmonary fibrosis (IPF) merely slow the rate of lung function decline and are associated with adverse events that affect medication adherence. Because of the high mortality rates that are associated with IPF, the need for efficacious treatments that meaningfully improve patients’ feeling and function, as well as survival, is evident and unmet.

“This well-conducted, multinational phase 3 trial undertaken to assess the efficacy and safety of pamrevlumab for patients with IPF failed to confirm it. Despite the disappointment with the negative results, the success lies in the patients who participated in this trial and adhered to the protocol amid all the challenges and hurdles of the COVID-19 pandemic and lessons gleaned will help better design of future trials.”

Contact information for Ganesh Raghu, M.D.: email graghu@uw.edu.

 

(doi:10.1001/jama.2024.8693)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial and Ethnic Inequities in Cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12050?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of patients with cancer and SARS-CoV-2, racial and ethnic inequities existed in treatment delays and discontinuations throughout the pandemic; however, the disproportionate burden among racially and ethnically minoritized patients with cancer varied across SARS-CoV-2 waves. These inequities may lead to downstream adverse impacts on cancer mortality among minoritized adults in the United States.

Corresponding Author: To contact the corresponding author, Jessica Y. Islam, Ph.D., M.P.H., email jessica.islam@moffitt.org.

 

(doi:10.1001/jamanetworkopen.2024.12050)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

A Comparison of Ukrainian Hospital Services and Functions Before and During the Russia-Ukraine War

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0901?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051724

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Measuring Primary Care Spending in the US by State

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0913?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051724

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Ultraprocessed Food Consumption and Cardiometabolic Risk Factors in Children

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 17, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.11852?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051724

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study suggest that high ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, highlighting the need for public health initiatives to promote the replacement of UPFs with unprocessed or minimally processed foods. 

Corresponding Author: To contact the corresponding author, Nancy Babio, Ph.D., email nancy.babio@urv.cat.

 

(doi:10.1001/jamanetworkopen.2024.11852)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Oropharyngeal Cancer Staging Health Record Extraction Using AI

Posted by Jim Michalski

JAMA Otolaryngology–Head & Neck Surgery

EMBARGOED FOR RELEASE: 4:15 P.M. (ET), THURSDAY, MAY 16, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at the American Head And Neck Society Annual Meeting at Combined Otolaryngology Spring Meetings 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2023.1201?guestAccessKey=d00c9284-3b48-4557-9d6f-7f4450d46156&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051624

 

About The Study: The results of this study suggest that artificial intelligence may be associated with enhanced patient care and oncological decision-making in patients with oropharyngeal squamous cell carcinoma through detection of localized versus advanced cancer stages. Further model refinement and external validation with electronic health records at different institutions are necessary to improve algorithm accuracy and clinical applicability.

Corresponding Author: To contact the corresponding author, Antoine Eskander, M.D., email antoine.eskander@mail.utoronto.ca.

 

(doi:10.1001/jamaoto.2023.1201)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Sex Differences in Primary Care–Based Chronic Kidney Disease Management

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:45 P.M. ET, THURSDAY, MAY 16, 2024

Media advisory: The full study is linked to this news release. The study is being released to coincide with presentation at the Society of General Internal Medicine annual meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8914?guestAccessKey=2d474e45-94e6-4eb2-8419-e90ef782683d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051624

 

About The Study: This study found significant sex differences in primary care–based chronic kidney disease management among patients at a care network affiliated with an academic medical center in the U.S., with females overall receiving worse care than males. Though many differences were of small magnitude, the disparity deserves further examination. 

Corresponding Author: To contact the corresponding author, Jorge A. Rodriguez, M.D., email jarodriguez1@partners.org.

 

(doi:10.1001/jama.2024.8914)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome

Posted by Jim Michalski

JAMA Dermatology

EMBARGOED FOR RELEASE: 5 P.M. (ET), FRIDAY, MARCH 17, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at the Society for Investigative Dermatology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.1804?guestAccessKey=f652fe63-9ce2-4011-aa0c-1a820be55a1f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051724

 

About The Study: This study found that BRCA1-associated protein (BAP1) tumor predisposition syndrome was associated with a high rate of nail abnormalities consistent with onychopapillomas (a benign tumor of the nail) in adult carriers of the disease. Findings suggest that this novel cutaneous sign may facilitate detection of the syndrome in family members who are at risk and patients with cancers associated with BAP1 given that multiple onychopapillomas are uncommon in the general population and may be a distinct clue to the presence of a pathogenic germline variant in the BAP1 gene.

Corresponding Authors: To contact the corresponding authors, email Edward W. Cowen, M.D., M.H.Sc. (cowene@mail.nih.gov) and Raffit Hassan, M.D. (hassanr@mail.nih.gov).

 

(doi:10.1001/jamadermatol.2024.1804)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Federal Trade Commission Actions on Prescription Drugs, 2000-2022

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5737?guestAccessKey=b5df0e55-79b2-4af8-9a64-87a6674156de&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

 

About The Study: The Federal Trade Commission (FTC) brought about one enforcement action and three merger actions per year against pharmaceutical manufacturers from 2000-2022, pursuing a small fraction of the estimated misconduct and consolidation in the pharmaceutical marketplace. Although the FTC faces substantial legal and practical limitations, important tools remain untested, including a rule defining “unfair methods of competition,” that may allow it to more effectively prevent repetitive patterns of anticompetitive behavior. 

Corresponding Author: To contact the corresponding author, Aaron S. Kesselheim, M.D., J.D., M.P.H., email akesselheim@bwh.harvard.edu.

 

(doi:10.1001/jama.2024.5737)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.1129?guestAccessKey=83379170-74be-4322-8664-95a85cc85fcc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051624

No Comments

Filed under:

Effectiveness of a Web-Based Cognitive Behavioral Self-Help Intervention for Binge Eating Disorder

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 16, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.11127?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this randomized clinical trial of a web-based self-help intervention for patients with binge eating disorder, the findings confirmed its effectiveness in reducing binge eating episodes and improving various mental health outcomes, highlighting a scalable solution to bridge the treatment gap for this condition. 

Corresponding Author: To contact the corresponding author, Luise Pruessner, M.S., email luise.pruessner@psychologie.uni-heidelberg.de.

 

(doi:10.1001/jamanetworkopen.2024.11127)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Physician and AI Chatbot Responses to Cancer Questions From Social Media

Posted by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 16, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.0836?guestAccessKey=7b38c33b-dcab-4eed-9996-3b74c559a0fa&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051624

 

About The Study: The findings of this study suggest that chatbots can generate quality, empathetic, and readable responses to patient questions comparable to physician responses sourced from an online forum. Further research is required to assess the scope, process integration, and patient and physician outcomes of chatbot-facilitated interactions. 

Corresponding Author: To contact the corresponding author, Srinivas Raman, M.D., M.A.Sc., email srinivas.raman@rmp.uhn.ca.

  

(doi:10.1001/jamaoncol.2024.0836)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Pediatric Trauma Center Access, Regional Injury Burden, and Socioeconomic Disadvantage

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2024.0962?guestAccessKey=456d0147-7d7f-415d-b355-10fe26522769&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051524

No Comments

Filed under:

Dose-Dependent Association Between Body Mass Index and Mental Health and Changes Over Time

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 15, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.0921?guestAccessKey=4de6c288-a9ff-4829-87ee-dba5000983cf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051524

 

About The Study: This study revealed a U-shaped association between adolescent body mass index and mental health, which was consistent across sex and grades and became stronger over time. These insights emphasize the need for targeted interventions addressing body image and mental health, and call for further research into underlying mechanisms. 

Corresponding Author: To contact the corresponding author, Shanquan Chen, Ph.D., email Shanquan.chen@lshtm.ac.uk.

 

(10.1001/jamapsychiatry.2024.0921)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Disparities in Patient Portal Engagement Among Patients With Hypertension Treated in Primary Care

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 15, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.11649?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cohort study of patients with hypertension found clear sociodemographic disparities in patient portal engagement among those treated in primary care. Without special efforts to engage patients with portals, interventions that use patient portals to target hypertension may exacerbate disparities. 

Corresponding Author: To contact the corresponding author, Rasha Khatib, Ph.D., M.H.S., email rasha.alkhatib@aah.org.

 

(doi:10.1001/jamanetworkopen.2024.11649)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

An Adaptive Behavioral Intervention for Weight Loss Management

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:01 P.M. ET, TUESDAY, MAY 14, 2024

Media advisory: The full study and editorial are linked to this news release. The study is being released to coincide with the European Congress on Obesity.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.0821?guestAccessKey=6d6633c0-8d44-48b2-a3eb-e97abf6c9a3a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051424

 

About The Study: A wireless feedback system (Wi-Fi activity tracker and scale with smartphone app to provide daily feedback) was not noninferior to the same system with added coaching. Continued efforts are needed to identify strategies for weight loss management and to accurately select interventions for different individuals to achieve weight loss goals.

 

Quote from corresponding author Bonnie Spring, Ph.D.:

 

“With U.S. obesity prevalence projected to reach 49% by 2030, limited obesity treatment resources need to be spread across more of the population.  One promising approach is stepped care that begins with low cost, self-monitoring technology alone, then intensifies treatment for those who show insufficient response.

 

“It has been unknown whether first line technology treatment alone could produce clinically acceptable weight loss.  In an adaptive randomized noninferiority trial, people who initially only received technology without coach support were less likely to achieve meaningful weight loss (5% of body weight), compared to those who had a human coach at the start.

 

“Currently, a human coach remains needed from the outset of obesity treatment because digital technology alone doesn’t produce clinically acceptable weight loss for most people.”

 

Contact information for Dr. Spring: email bspring@northwestern.edu.

 

(doi:10.1001/jama.2024.0821)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Text Messages With Financial Incentives for Men With Obesity

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:01 P.M. ET, TUESDAY, MAY 14, 2024

Media advisory: The full study and editorial are linked to this news release. The study is being presented at the European Congress on Obesity.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7064?guestAccessKey=e5e4f13d-f93c-4d64-b9fb-c579e4b06a33&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051424

 

About The Study: Among men with obesity, an intervention with text messaging with financial incentive significantly improved weight loss compared with a control group, whereas text messaging alone was not significantly better than the control condition. These findings support text messaging combined with financial incentives to attain weight loss in men with obesity.

 

Quote from corresponding author Prof. Pat Hoddinott, M.B., B.S., Ph.D.:

 

“Losing weight can make people feel better, reduce their risk of many health problems such as diabetes, and helps the health service with their aim to keep men well. However, we know men often don’t like to go to traditional weight loss groups.

 

“This was a very carefully planned study, created for men by men. We worked closely with various men’s health groups and charities, including Men’s Health Forum in the UK and Ireland, with more than 1000 men living with obesity informing the design of the incentive structure.

 

“The research showed that offering cash incentives was a popular and effective way of helping men to lose weight. This initiative would be a low-cost solution for the health service to offer to men, requiring only four short weight appointments, and with money paid out only at the end to those who lose over 5% of their starting weight.”

 

Contact information for Prof. Hoddinott:

Press officer: Sarah Manning, sarah.manning@stir.ac.uk; 01786 466436 / 07341 052 750.

 

(doi:10.1001/jama.2024.7064)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Cardiovascular Burden of the V142I Transthyretin Variant

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3:30 A.M. ET, SUNDAY, MAY 12, 2024

Media advisory: The full study and editorials are linked to this news release. The study is being released to coincide with presentation at the European Society of Cardiology-Heart Failure Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.4467?guestAccessKey=c95f4af2-1de1-43d4-9a0d-82f414e05f8d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051224

 

About The Study: Among self-reported Black individuals, male and female V142I carriers faced similar and substantial risk for heart failure hospitalization, predominantly with reduced ejection fraction, and death, with steep age-dependent penetrance. Delineating the individual contributions of, and complex interplay among, the V142I variant, ancestry, the social construct of race, and biological or social determinants of health to cardiovascular disease merits further investigation. 

Corresponding Author: To contact the corresponding author, Scott D. Solomon, M.D., email ssolomon@rics.bwh.harvard.edu.

 

(doi:10.1001/jama.2024.4467)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 15, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7395?guestAccessKey=93a190ab-5a8a-4dcb-b76f-129dd3bafa63&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051524

 

About The Study: This study found that in fall-winter 2023-2024, the risk of death in patients hospitalized for COVID-19 was greater than the risk of death in patients hospitalized for seasonal influenza. 

Corresponding Author: To contact the corresponding author, Ziyad Al-Aly, M.D., email ziyad.alaly@va.gov.

 

(doi:10.1001/jama.2024.7395)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Effect of Low-Dose Iron Supplementation on Early Development in Breastfed Infants

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1095?guestAccessKey=0e384640-de01-43ce-9a3c-67a6d26c1381&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051324

No Comments

Filed under:

Telehealth Expansion and Medicare Beneficiaries’ Care Quality and Access

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 13, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.11006?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051324

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study of Medicare beneficiaries across all 3,436 hospital service areas (HSAs), high levels of telehealth use were associated with more clinician encounters, more ambulatory care–sensitive hospitalizations, and higher total health care costs. COVID-19 cases were still high during the period of study, which suggests that these findings partially reflect a higher capacity for providing health services in HSAs with higher telehealth intensity than other HSAs. 

Corresponding Author: To contact the corresponding author, Sara Parker-Lue, Ph.D., email sparkerlue@air.org.

 

(doi:10.1001/jamanetworkopen.2024.11006)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 13, 2024

Media advisory: The full study and Viewpoint are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.1476?guestAccessKey=b1e95fa9-c670-485e-bb0e-864019276c9f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051324

 

About The Study: The findings of this cohort study indicate that mail-order pharmacy dispensing of mifepristone for medication abortion was effective, acceptable to patients, and feasible, with a low prevalence of serious adverse events. This care model should be expanded to improve access to medication abortion services. 

Corresponding Author: To contact the corresponding author, Daniel Grossman, M.D., email daniel.grossman@ucsf.edu.

 

(doi:10.1001/jamainternmed.2024.1476)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Causal Inference About the Effects of Interventions From Observational Studies in Medical Journals

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:30 A.M. ET, THURSDAY, MAY 9, 2024

Media advisory: The full study and editor’s note are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7741?guestAccessKey=4a0c808a-a6e6-47b1-b44f-336494081397&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050924

 

About The Study: Adoption of the proposed framework to identify when causal interpretation is appropriate in observational studies promises to facilitate better communication between authors, reviewers, editors, and readers. Practical implementation will require cooperation between editors, authors, and reviewers to operationalize the framework and evaluate its effect on the reporting of empirical research. 

Corresponding Author: To contact the corresponding author, Issa J. Dahabreh, M.D., Sc.D., email idahabreh@hsph.harvard.edu.

 

(doi:10.1001/jama.2024.7741)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Nurse Practitioner Care, Scope of Practice, and End-of-Life Outcomes for Nursing Home Residents With Dementia

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0825?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051024

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Social Determinants of Health and Delivery of Rehabilitation to Older Adults During ICU Hospitalization

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 10, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.10713?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study highlight the need to consider social determinants of health in efforts to promote rehabilitation delivery during intensive care unit (ICU) hospitalization and to investigate factors underlying inequities in this practice. 

Corresponding Author: To contact the corresponding author, Snigdha Jain, M.D., M.H.S., email Snigdha.Jain@yale.edu.

 

(doi:10.1001/jamanetworkopen.2024.10713)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Long-Term Effect of Home Blood Pressure Self-Monitoring Plus Medication Self-Titration for Patients With Hypertension

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 10, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.10063?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this secondary analysis of a randomized clinical trial, blood pressure (BP) self-monitoring plus self-titration of antihypertensive medication based on an individualized prearranged plan used in primary care reduced BP in the longer term with passive follow-up compared with usual care, without increasing health care use or adverse events. These results suggest that simple, inexpensive, and easy-to-implement self-management interventions have the potential to improve the long-term control of hypertension in routine clinical practice. 

Corresponding Author: To contact the corresponding author, Gabriel Sanfelix-Gimeno, Ph.D., email gabriel.sanfelix@fisabio.es.

 

(doi:10.1001/jamanetworkopen.2024.10063)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prognostic Value of Cardiovascular Biomarkers in the Population

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 13, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5596?guestAccessKey=0c8356ed-b996-4dd8-a4b6-5d654d24e31b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051324

 

About The Study: Cardiovascular biomarkers were strongly associated with fatal and nonfatal cardiovascular events and mortality. The addition of biomarkers to established risk factors led to only a small improvement in risk prediction metrics for atherosclerotic cardiovascular disease, but was more favorable for heart failure and mortality. 

Corresponding Author: To contact the corresponding author, Johannes Tobias Neumann, M.D., Ph.D., email j.neumann@uke.de.

 

(doi:10.1001/jama.2024.5596)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Diversity, Equity, and Inclusion Content on Ophthalmology Fellowship Webpages

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.1215?guestAccessKey=093163f0-ae47-49c4-9b27-02dda6561a8e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050924

No Comments

Filed under:

Declination of Treatment, Racial and Ethnic Disparity, and Overall Survival in Patients With Breast Cancer

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 9, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.9449?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study highlights racial and ethnic disparities in treatment declination and overall survival, suggesting the need for equity-focused interventions, such as patient education on treatment benefits and improved patient-clinician communication and shared decision-making, to reduce disparities and improve patient survival. 

Corresponding Author: To contact the corresponding author, Dezheng Huo, M.D., Ph.D., email dhuo@bsd.uchicago.edu.

 

(doi:10.1001/jamanetworkopen.2024.9449)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Place-Based Measures of Inequity and Vision Difficulty and Blindness

Posted by Jim Michalski

JAMA Ophthalmology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 9, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.1207?guestAccessKey=732262b4-8ed7-42f0-b26a-1123152e8787&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050924

 

About The Study: Residential measures of inequity through segregation, income inequality, or persistent poverty were associated with a greater number of residents living with vision difficulty and blindness in this cross-sectional study. It is essential to understand and address how neighborhood characteristics can impact rates of vision difficulty and blindness. 

Corresponding Author: To contact the corresponding author, Patrice M. Hicks, Ph.D., M.P.H., email pmhicks@med.umich.edu.

 

(doi:10.1001/jamaophthalmol.2024.1207)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Burden of Mental Disorders and Suicide Attributable to Childhood Maltreatment

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.0804?guestAccessKey=d319708e-6c98-44ea-a319-105182830fad&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050824

No Comments

Filed under:

Role of Inflammation in Short Sleep Duration Across Childhood and Psychosis in Young Adulthood

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.0796?guestAccessKey=b08c8535-249c-47d3-9951-8b631fc38c91&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050824

No Comments

Filed under:

Sexual Harassment, Abuse, and Discrimination in Obstetrics and Gynecology

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 8, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.10706?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study suggest that there is a high prevalence of harassment in OB-GYN despite being a predominantly female field for the last decade. 

Corresponding Author: To contact the corresponding author, Ankita Gupta, M.D., M.P.H., email ankita.gupta@louisville.edu.

 

(doi:10.1001/jamanetworkopen.2024.10706)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Estimated Number of Children Who Lost a Parent to Drug Overdose in the US From 2011 to 2021

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 8, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.0810?guestAccessKey=c857864f-b4a7-4c5f-a619-941cef098745&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050824

 

About The Study: More than 320,000 children in the U.S. lost a parent to drug overdose between 2011-2021, with significant disparities evident across racial and ethnic groups. Given the potential short- and long-term negative impact of parental loss, program and policy planning should ensure that responses to the overdose crisis account for the full burden of drug overdose on families and children, including addressing the economic, social, educational, and health care needs of children who have lost parents to overdose. 

Corresponding Author: To contact the corresponding author, Christopher M. Jones, Pharm.D., Dr.P.H., M.P.H., email christopher.jones@samhsa.hhs.gov.

 

(10.1001/jamapsychiatry.2024.0810)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 8, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.6892?guestAccessKey=3797feb1-0b89-4e9a-8654-85c8ae964ffe&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050824

 

About The Study: Almost 90% of U.S. adults met criteria for cardiovascular, kidney, and metabolic (CKM) syndrome (stage 1 or higher) and 15% met criteria for advanced stages, neither of which improved between 2011 and 2020. Substantial between-subgroup differences in advanced stages were observed, with older age, men, and Black adults at increased risk. Cardiovascular, kidney, and metabolic diseases are pathophysiologically interrelated and were the leading causes of death in 2021. In 2023, the American Heart Association introduced a novel staging construct, termed CKM syndrome, to enhance multidisciplinary approaches to prevention, risk stratification, and management of these disorders.

Corresponding Author: To contact the corresponding author, Muthiah Vaduganathan, M.D., M.P.H., email mvaduganathan@bwh.harvard.edu.

 

(doi:10.1001/jama.2024.6892)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Multilevel Characteristics of Cumulative Symptom Burden in Young Survivors of Childhood Cancer

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 7, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.10145?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050724

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study suggest that symptoms are prevalent years after young childhood cancer survivors’ initial cancer diagnosis, and interventions to reduce caregiver anxiety and neighborhood adversity and improve resilience may alleviate symptom burden. 

Corresponding Author: To contact the corresponding author, I-Chan Huang, Ph.D., email i-chan.huang@stjude.org.

  

(doi:10.1001/jamanetworkopen.2024.10145)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Social Determinants of Health and the Availability of Cancer Clinical Trials in the US

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 7, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.10162?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050724

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Substantial geographic disparities in cancer clinical trials availability exist throughout the United States, with the most socially vulnerable counties being far less likely to have any trial and having only a fraction of trials available, a disparity that has worsened over time. 

Corresponding Author: To contact the corresponding author, Rishi Robert Sekar, M.D., M.S., email rsekar@med.umich.edu. 

 

(doi:10.1001/jamanetworkopen.2024.10162)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.1313?guestAccessKey=24efccda-d2a7-44a1-abb0-c7cfa76b9f28&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050624

No Comments

Filed under:

Behavioral Interventions to Improve Breast Cancer Screening Outreach

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 6, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.0507?guestAccessKey=9e01539d-9467-4125-9773-4973700b3967&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050624

 

About The Study: These findings show that text messaging women after initial breast cancer screening outreach via either electronic portal or mailings, as well as bulk ordering with or without text messaging, can increase mammogram completion rates.  

Corresponding Author: To contact the corresponding author Shivan J. Mehta, M.D., M.B.A., M.S.H.P., email shivan.mehta@pennmedicine.upenn.edu.

 

(doi:10.1001/jamainternmed.2024.0507)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial and Ethnic Disparities in Initiation of Direct Oral Anticoagulants Among Medicare Beneficiaries

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 6, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.9465?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study of Medicare patients with atrial fibrillation, Black and Hispanic patients were less likely to initiate direct oral anticoagulants for atrial fibrillation, although these differences diminished over time. Identifying the factors behind these early disparities is crucial for ensuring equitable access to novel therapies as they emerge for Black and Hispanic populations. 

Corresponding Authors: To contact the corresponding authors, email Kamika R. Reynolds, M.S., Ph.D. (kreynolds@ifh.rutgers.edu) and Chintan V. Dave, Pharm.D., Ph.D. (cdave@ifh.rutgers.edu). 

 

(doi:10.1001/jamanetworkopen.2024.9465)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial and Ethnic Disparities in All-Cause and Cause-Specific Mortality Among US Youth

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3:30 P.M. (ET), SATURDAY, MAY 4, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being released to coincide with presentation at the Pediatric Academic Societies meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.3908?guestAccessKey=964d2832-89ff-4409-a3a0-b96e343165cb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050424

 

About The Study: Racial and ethnic disparities were observed for almost all leading causes of injury and disease that were associated with recent increases in youth mortality rates. Addressing the increasing disparities affecting American Indian or Alaska Native and Black youth will require efforts to prevent homicide and suicide, especially those events involving firearms. 

Authors: Elizabeth R. Wolf, M.D., M.P.H., of the Virginia Commonwealth University School of Medicine in Richmond, is the corresponding author.

 

(doi:10.1001/jama.2024.3908)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Loss of Medicaid Coverage During the Renewal Process

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0839?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050324

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Associations of Internal Medicine Residency Milestone Ratings and Certification Examination Scores With Patient Outcomes

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5268?guestAccessKey=3a35b91c-5a8a-435f-977f-8f1242a11094&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050624

No Comments

Filed under:

Long-Term Cardiovascular Outcomes in Children and Adolescents With Hypertension

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 9 A.M. (ET), MONDAY, MAY 6, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at the Pediatric Academic Societies meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1543?guestAccessKey=629b52f1-cf25-4fcb-86b2-cd4d43237377&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050624

 

About The Study: Children diagnosed with hypertension had a higher associated long-term risk of major adverse cardiac events compared with controls without hypertension. Improved detection, follow-up, and control of pediatric hypertension may reduce the risk of adult cardiovascular disease. 

Authors: Rahul Chanchlani, M.B.B.S., M.D., M.Sc., of McMaster University in Hamilton, Canada, is the corresponding author.

 

(doi:10.1001/jamapediatrics.2024.1543)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under: